Michele C. Livesey, BS, MBA, brings to DIA more than two decades of drug development experience through managing and leading strategy and drug development projects for Genentech, Inc., Barrier Therapeutics, Roche, and Afferent Pharmaceuticals. Michele has worked on monoclonal antibodies and small molecules in all stages of drug development through commercialization, including collaborations with international partners; her therapeutic experience includes oncology, dermatology, cardiovascular, virology, immunology, and pain. She is Founder and President of Livesey Consulting, which is focused on helping companies reach important drug development milestones and build and execute strategies. She previously served as Vice President of Development Operations for Afferent Pharmaceuticals, where she was responsible for the staffing and oversight of non-clinical (toxicology and DMPK), CMC, regulatory, QA, project management, and general business operations. Michele has served DIA for more than a decade as an Annual Meeting speaker, session chair, and track chair, and has also provided leadership to the DIA Project Management Community. Michele earned her BS in Biological Sciences from California Polytechnic State University, San Luis Obispo, and her MBA with honors from Golden Gate University with an emphasis in Marketing & Operations and Supply Chain Management.